目的:前庭大腺腺样囊性癌(AdCC-BG)是一种非常罕见的妇科外阴恶性肿瘤。AdCC-BG生长缓慢,但具有局部侵袭性,并与高复发率相关。在这里,我们试图表征AdCC-BG的分子基础。
方法:AdCC-BG(n=6)进行RNA测序,靶向DNA测序,逆转录PCR,荧光原位杂交(FISH)和MYB免疫组织化学(IHC)。临床病理变量,体细胞突变,评估拷贝数改变和嵌合转录本。
结果:所有六个AdCC-BG均为双相,由导管和肌上皮细胞组成。类似于唾液腺和乳腺AdCC,三个AdCC-BG具有不同断点的MYB::NFIB融合基因,所有这些都与IHC的MYB过表达有关。两个AdCC-BG以MYBL1融合基因与不同的基因伴侣为基础,包括MYBL1::RAD51B和MYBL1::EWSR1基因融合,并显示MYB蛋白表达。尽管最终研究的AdCC-BG具有MYB蛋白过表达,没有发现基因融合。AdCC-BG几乎没有其他体细胞遗传改变,在癌症相关基因中只发现了很少的突变,包括GNAQ,GNAS,KDM6A,AKT1和BCL2,均未复发。两个AdCC-BG,两者都具有MYB::NFIB融合基因,发展为转移性疾病。
结论:AdCC-BG构成趋同表型,由此MYB或MYBL1的激活可由MYB::NFIB融合基因或MYBL1重排驱动。我们的观察进一步支持这样一种观点,即AdCC,不管器官部位,构成基因型-表型相关性。MYB或MYBL1重排的评估可用作诊断AdCC-BG的辅助标记。
Adenoid cystic carcinoma (AdCC) of the Bartholin\'s gland (AdCC-BG) is a very rare gynecologic vulvar malignancy. AdCC-BGs are slow-growing but locally aggressive and are associated with high recurrence rates. Here we sought to characterize the molecular underpinning of AdCC-BGs.
AdCC-BGs (n = 6) were subjected to a combination of RNA-sequencing, targeted DNA-sequencing, reverse-transcription PCR, fluorescence in situ hybridization (FISH) and MYB immunohistochemistry (IHC). Clinicopathologic variables, somatic mutations, copy number alterations and chimeric transcripts were assessed.
All six AdCC-BGs were biphasic, composed of ductal and myoepithelial cells. Akin to salivary gland and breast AdCCs, three AdCC-BGs had the MYB::NFIB fusion gene with varying breakpoints, all of which were associated with MYB overexpression by IHC. Two AdCC-BGs were underpinned by MYBL1 fusion genes with different gene partners, including MYBL1::RAD51B and MYBL1::EWSR1 gene fusions, and showed MYB protein expression. Although the final AdCC-BG studied had MYB protein overexpression, no gene fusion was identified. AdCC-BGs harbored few additional somatic genetic alterations, and only few mutations in cancer-related genes were identified, including GNAQ, GNAS, KDM6A, AKT1 and BCL2, none of which were recurrent. Two AdCC-BGs, both with a MYB::NFIB fusion gene, developed metastatic disease.
AdCC-BGs constitute a convergent phenotype, whereby activation of MYB or MYBL1 can be driven by the MYB::NFIB fusion gene or MYBL1 rearrangements. Our observations further support the notion that AdCCs, irrespective of organ site, constitute a genotypic-phenotypic correlation. Assessment of MYB or MYBL1 rearrangements may be used as an ancillary marker for the diagnosis of AdCC-BGs.